Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

Safety and Biologic Activity Data Reviewed in End of Phase 2a Meeting

SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company's lead drug, VIA-2291 (atreleuton), was recently held with the U.S. Food and Drug Administration (FDA). The Company reviewed safety and biologic activity data from the VIA-2291 Phase 2 CEA and ACS trials with the FDA and received guidance including suggestions from the Agency on the Company's Phase 3 trial design.

VIA-2291 is a selective and reversible inhibitor of 5 Lipoxygenase, a key enzyme in the biosynthesis of leukotrienes, which are important mediators of the inflammation believed to be involved in the development and progression of atherosclerosis. The Company's Phase 3 cardiovascular outcome study will assess the effect of VIA-2291 in preventing cardiovascular events such as heart attack, stroke and cardiovascular mortality in patients with recent heart attack and/or established atherosclerotic cardiovascular disease. Guidance from the FDA will be incorporated into the VIA-2291 registration and Phase 3 program, and the company intends to submit its proposed Phase 3 plan to FDA including a request for a Special Protocol Assessment. The Company is currently exploring strategic opportunities for launching this final phase of development.

"The current treatment approaches have reached their potential, and yet there still exists a significant unmet medical need in heart disease, particularly in patients at high risk for heart attacks, strokes and cardiovascular death," said Larry Cohen, President and Chief Executive Officer of VIA Pharmaceuticals, Inc. "VIA-2291 specifically
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today ... Heaton to the Board of Directors. QMC also announced formation ... , QMC Chief Science Officer and Board of Directors Member, along ... Rice University and Mr. Tomio Gotoh , a pioneer of ... " Quantum Materials welcomes two new outside Board members, ...
(Date:7/22/2014)... , July 22, 2014 ... and device company focused on solid dose formulations ... novel solid formulation of octreotide acetate achieved successful ... with the currently marketed liquid product (Sandostatin®).  Based ... the formulation production process to a contract manufacturing ...
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a ... supplements , will celebrate its first anniversary in August. ... is designed to enhance the body,s ability to produce ... that is made up of a variety of phytonutrients ... have been found to increase nitric oxide ...
Breaking Medicine Technology:Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
(Date:7/22/2014)... American Society of Hematology (ASH) will present the Society,s ... Lifetime Achievement in Hematology, to Kanti R. Rai, MD, ... of Medicine for his 50-year career combining landmark clinical ... exceptional patient care. , The Wallace H. Coulter ... an individual who has been a vital contributor to ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... 27 Ten Big Brothers Big Sisters agencies will receive ... "engaging parents as partners" to help children improve their odds ... Sisters is the nation,s largest donor-supported volunteer mentoring network with ... incarcerated parents, with a focus on breaking negative cycles. ...
... , , ISELIN, N.J., Aug. 27 ... for PharmSep: LCGC,s Symposium for Separation Scientists in Pharmaceuticals. The ... DeLand, Pharmaceutical Market Development Manager, Dionex Corporation , and ... will take place in Philadelphia, PA, on September 21-22, 2009. ...
... , , , ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic ... organization has signed a Master Services Agreement (MSA) to use ... Thorough QT (TQT) and Phase 1 studies delivered by its ...
... Dr. ... win the battle against the epidemic of untreated sleep apnea by offering special incentives to ... ... Southern California sleep apnea expert, has found a way to help patients win the battle ...
... ... Announcing an exciting innovation in antimicrobial coatings: OxiTitan VLR. The ... power of light. Durable and easily applied to existing interior surfaces ... utilizing normal incandescent or flourescent lighting. The continuously active photocatalyst traps ...
... ... reduce operating costs and improve efficiencies for homecare providers. , ... (Vocus) August 27, ... improve productivity for homecare providers., , , , ,According to Spencer Kay, President ...
Cached Medicine News:Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 2Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 3Health News:LCGC Announces the Agenda for Their Upcoming PharmSep Conference 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 3Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 4Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 2Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 3Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 2Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 3Health News:New Fastrack Technology Improves Productivity 2Health News:New Fastrack Technology Improves Productivity 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: